Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Budget Proposal Shifts More Toward User Fees Reliance

This article was originally published in The Tan Sheet

Executive Summary

User fees make up the bulk of FDA’s human drug spending under President Obama’s fiscal 2014 budget proposal, a trend fueled by new user fee programs and cuts to taxpayer funding.

You may also be interested in...



New Food And Drug User Fees Face Long Odds In Congress

FDA’s $4.7 billion fiscal 2014 budget request proposes new fees including $58.9 million from food establishment registrations and inspections, $19.1 million from cosmetics firms and $15.04 million from medical product reinspections.

Biosimilars: Does Low BsUFA Fee Revenue Suggest Sponsor Interest Has Stalled?

Halfway through the first year of the biosimilar user fee program, fee payments have not lived up to the expectation in President Obama’s FY 2013 budget request. Initial meetings continue to grow but at a slow pace, suggesting sponsors may remain hesitant about the pathway.

HELP Committee Leaders Add Voice To Doubts About New User Fees

HELP Chairman Harkin and ranking member Enzi say potential riders added to the FDA user fee bill could slow down passage and add more work for agency staff. The senators’ concern follows House appropriators’ doubts as obstacles to approval for new food safety user fees.

Related Content

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel